| |
| |
|
| Insider
Information: |
Cui Jingrong Jean |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,001,298 |
|
|
Indirect Shares
|
840,383 |
|
|
| Direct
Value |
$76,108,661 |
|
|
|
Indirect Value
|
$63,877,512 |
|
|
| Total
Shares |
1,841,681 |
|
|
| Total
Value |
$139,986,173 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2020-06-09 |
1,001,298 |
2020-06-09 |
840,383 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
57 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-06-27 |
4 |
OE |
$5.12 |
$277,606 |
I/I |
54,220 |
835,439 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-05 |
4 |
AS |
$50.93 |
$2,914,936 |
I/I |
(56,110) |
1,123,109 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-06 |
4 |
AS |
$50.67 |
$2,583,588 |
I/I |
(50,890) |
1,072,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-09 |
4 |
AS |
$54.33 |
$636,229 |
I/I |
(11,500) |
1,060,719 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-10 |
4 |
AS |
$53.79 |
$627,631 |
I/I |
(11,500) |
1,049,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-11 |
4 |
AS |
$52.72 |
$608,787 |
I/I |
(11,500) |
1,037,719 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-12 |
4 |
AS |
$53.18 |
$622,291 |
I/I |
(11,500) |
1,026,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-13 |
4 |
AS |
$55.43 |
$641,169 |
I/I |
(11,500) |
1,014,719 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-16 |
4 |
AS |
$55.45 |
$671,077 |
I/I |
(11,500) |
1,003,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-17 |
4 |
AS |
$60.30 |
$1,134,374 |
I/I |
(18,500) |
984,719 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-18 |
4 |
AS |
$57.76 |
$1,095,170 |
I/I |
(18,500) |
966,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-19 |
4 |
AS |
$59.84 |
$1,130,257 |
I/I |
(18,500) |
947,719 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2019-12-20 |
4 |
AS |
$62.64 |
$729,150 |
I/I |
(11,500) |
936,219 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-12-27 |
4 |
OE |
$3.20 |
$179,456 |
I/I |
38,080 |
873,519 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2019-12-30 |
4 |
OE |
$5.12 |
$86,344 |
I/I |
16,864 |
890,383 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-10 |
4 |
AS |
$54.00 |
$1,067,161 |
I/I |
(18,500) |
917,719 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-13 |
4 |
AS |
$52.49 |
$978,073 |
I/I |
(18,500) |
899,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-14 |
4 |
AS |
$52.44 |
$990,811 |
I/I |
(18,500) |
880,719 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-15 |
4 |
AS |
$53.03 |
$610,853 |
I/I |
(11,500) |
869,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-27 |
4 |
AS |
$56.82 |
$403,652 |
I/I |
(7,000) |
862,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-28 |
4 |
AS |
$58.18 |
$408,529 |
I/I |
(7,000) |
855,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Chief Scientific Officer |
• • – |
2020-01-29 |
4 |
AS |
$58.39 |
$411,104 |
I/I |
(7,000) |
848,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2020-02-10 |
4 |
AS |
$62.75 |
$1,164,482 |
I/I |
(18,500) |
829,719 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2020-02-11 |
4 |
AS |
$63.03 |
$1,169,668 |
I/I |
(18,500) |
811,219 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
Director |
– • – |
2020-02-12 |
4 |
AS |
$65.31 |
$1,219,594 |
I/I |
(18,500) |
792,719 |
0 |
% |
|
57 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
